Natural killer cell activity in prostate cancer patients treated with curative radiotherapy with or without androgen deprivation therapy: an observational study
DOI:
https://doi.org/10.2340/1651-226X.2025.44007Keywords:
Natural killer cells, Prostate cancer, Radiotherapy, Androgen deprivation therapy, Immune biomarkersAbstract
Background and purpose: Natural killer (NK) cells play an important role in defense against cancer. Low NK cell activity (NKA) has been linked to prostate cancer (PCa) detection, and effective NKA may be associated with better prognosis in metastatic PCa. Radiotherapy (RT) could affect the immune response, but data on NKA in patients with PCa receiving RT ± androgen deprivation therapy (ADT) remain limited. Hence, this study investigated NKA in such patients.
Patient/material and methods: Peripheral blood from 150 patients with PCa receiving curatively intended RT was collected into NK Vue® tubes prior to RT (baseline, BL), after end of RT (EOT), and during follow-up. Patients received 0- (n = 15), 6- (n = 23), or 36-months of ADT (n = 112), starting 3 months before RT. Interferon-γ was a surrogate marker for NKA in NK Vue® tubes. Data were analyzed using descriptive statistics.
Results: Baseline characteristics were similar between patients with normal (≥ 250 pg/mL) (n = 46) and low (< 250 pg/mL) (n = 104) NKA; however, smoking was more prevalent in the low NKA group (28% vs. 11%). The distribution of NKA levels differed between groups and time points, notably showing a decreased interquartile range (IQR) for all groups at EOT (BL median 832 pg/mL, IQR 2901; EOT median 312 pg/mL, IQR 708). NKA fluctuated during follow-up and did not mirror prostate-specific antigen dynamics.
Interpretation: Patients with localized PCa treated with RT ± ADT displayed marked variation in NKA, including treatment-related dynamics. The overall complexity and heterogeneity of NKA raise questions about its clinical utility as a biomarker in this setting.
Downloads
References
Bhardwaj N, Farkas AM, Gul Z, Sfakianos JP. Harnessing natural killer cell function for genitourinary cancers. Urol Clin North Am. 2020;47(4):433–42.
https://doi.org/10.1016/j.ucl.2020.07.002 DOI: https://doi.org/10.1016/j.ucl.2020.07.002
Wolf NK, Kissiov DU, Raulet DH. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat Rev Immunol. 2023;23(2):90–105.
https://doi.org/10.1038/s41577-022-00732-1 DOI: https://doi.org/10.1038/s41577-022-00732-1
Han J, Wu M, Liu Z. Dysregulation in IFN-γ signaling and response: the barricade to tumor immunotherapy. Front Immunol. 2023;14:1190333.
https://doi.org/10.3389/fimmu.2023.1190333 DOI: https://doi.org/10.3389/fimmu.2023.1190333
Freud AG, Mundy-Bosse BL, Yu J, Caligiuri MA. The broad spectrum of human natural killer cell diversity. Immunity. 2017;47(5):820–33.
https://doi.org/10.1016/j.immuni.2017.10.008 DOI: https://doi.org/10.1016/j.immuni.2017.10.008
Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000;356(9244):1795–9.
https://doi.org/10.1016/S0140-6736(00)03231-1 DOI: https://doi.org/10.1016/S0140-6736(00)03231-1
Vidal AC, Howard LE, Wiggins E, De Hoedt AM, Shiao SL, Knott S, et al. Natural killer cell activity and prostate cancer risk in veteran men undergoing prostate biopsy. Cancer Epidemiol. 201962:101578.
https://doi.org/10.1016/j.canep.2019.101578 DOI: https://doi.org/10.1016/j.canep.2019.101578
Barkin J, Rodriguez-Suarez R, Betito K. Association between natural killer cell activity and prostate cancer: a pilot study. Can J Urol. 2017;24(2):8708–13.
Tae BS, Jeon BJ, Lee YH, Choi H, Park JY, Bae JH. Can natural killer cell activity help screen patients requiring a biopsy for the diagnosis of prostate cancer? Int Braz J Urol Off J Braz Soc Urol. 2020;46(2):244–52.
https://doi.org/10.1590/s1677-5538.ibju.2019.0268 DOI: https://doi.org/10.1590/s1677-5538.ibju.2019.0268
Koo KC, Shim DH, Yang CM, Lee S-B, Kim SM, Shin TY, et al. Reduction of the CD16−CD56bright NK cell subset precedes NK cell dysfunction in prostate cancer. PLoS One. 2013;8(11):e78049.
https://doi.org/10.1371/journal.pone.0078049 DOI: https://doi.org/10.1371/journal.pone.0078049
Lu Y-C, Kuo M-C, Hong J-H, Jaw F-S, Huang C-Y, Cheng JC-H, et al. Lower postoperative natural killer cell activity is associated with positive surgical margins after radical prostatectomy. J Formos Med Assoc. 2020;119(11):1673–83.
https://doi.org/10.1016/j.jfma.2019.12.015 DOI: https://doi.org/10.1016/j.jfma.2019.12.015
Song W, Yu JW, Jeong BC, Seo SI, Jeon SS, Lee HM, et al. The clinical usefulness of natural killer cell activity in patients with suspected or diagnosed prostate cancer: an observational cross-sectional study. OncoTargets Ther. 2018;11:3883–9.
https://doi.org/10.2147/OTT.S169094 DOI: https://doi.org/10.2147/OTT.S169094
Wu J. Could harnessing natural killer cell activity be a promising therapy for prostate cancer. Crit Rev Immunol. 2021;41(2):101–6.
https://doi.org/10.1615/CritRevImmunol.2021037614 DOI: https://doi.org/10.1615/CritRevImmunol.2021037614
Zheng W, Ling S, Cao Y, Shao C, Sun X. Combined use of NK cells and radiotherapy in the treatment of solid tumors. Front Immunol. 2024;14:1306534.
https://doi.org/10.3389/fimmu.2023.1306534 DOI: https://doi.org/10.3389/fimmu.2023.1306534
Supiot S, Rousseau C, Dore M, Chèze-Le-Rest C, Kandel-Aznar C, Potiron V, et al. Reoxygenation during radiotherapy in intermediate-risk prostate cancer. Radiother Oncol. 2019;133:16–9.
https://doi.org/10.1016/j.radonc.2018.12.022 DOI: https://doi.org/10.1016/j.radonc.2018.12.022
Mainta IC, Zilli T, Tille J-C, De Perrot T, Vallée J-P, Buchegger F, et al. The effect of neoadjuvant androgen deprivation therapy on tumor hypoxia in high-grade prostate cancer: an 18F-MISO PET-MRI study. Int J Radiat Oncol. 2018;102(4):1210–8.
https://doi.org/10.1016/j.ijrobp.2018.02.170 DOI: https://doi.org/10.1016/j.ijrobp.2018.02.170
Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson A-M, Saad F. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods. 2009;348(1):9–17.
https://doi.org/10.1016/j.jim.2009.06.004 DOI: https://doi.org/10.1016/j.jim.2009.06.004
Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci J Virtual Libr. 2007;12:
4957–71.
https://doi.org/10.2741/2441 DOI: https://doi.org/10.2741/2441
Page ST, Plymate SR, Bremner WJ, Matsumoto AM, Hess DL, Lin DW, et al. Effect of medical castration on CD4+CD25+ T cells, CD8+ T cell IFN-γ expression, and NK cells: a physiological role for testosterone and/or its metabolites. Am J Physiol-Endocrinol Metab. 2006;290(5):E856–63.
https://doi.org/10.1152/ajpendo.00484.2005 DOI: https://doi.org/10.1152/ajpendo.00484.2005
Morse MD, McNeel DG. Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. Hum Immunol. 2010;71(5):496–504.
https://doi.org/10.1016/j.humimm.2010.02.007 DOI: https://doi.org/10.1016/j.humimm.2010.02.007
Jochems C, Madan RA, Fernando RI, Gulley JL, Tsang KY, Schlom J. Abstract 1406: analysis of immune responses as a consequence of androgen deprivation therapy in patients with biochemical progression of prostate cancer. Cancer Res. 2016;76(14_Suppl):1406.
https://doi.org/10.1158/1538-7445.AM2016-1406 DOI: https://doi.org/10.1158/1538-7445.AM2016-1406
Cornford P, Tilki D, van den Bergh RCN, Eberli D, De Meerleer G, De Santis M, et al. EAU – EANM – ESTRO – ESUR – ISUP – SIOG guidelines on prostate cancer. EAU Annual Congress, Madrid. Arnhem: EAU Guidelines Office; 2025.
Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965–74.
https://doi.org/10.1016/j.ijrobp.2006.04.029 DOI: https://doi.org/10.1016/j.ijrobp.2006.04.029
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147(8):573–7.
https://doi.org/10.7326/0003-4819-147-8-200710160-00010 DOI: https://doi.org/10.7326/0003-4819-147-8-200710160-00010
Nederby L, Jakobsen A, Hokland M, Hansen TF. Quantification of NK cell activity using whole blood: methodological aspects of a new test. J Immunol Methods. 2018;458:21–5.
https://doi.org/10.1016/j.jim.2018.04.002 DOI: https://doi.org/10.1016/j.jim.2018.04.002
Kerkmeijer LGW, Groen VH, Pos FJ, Haustermans K, Monninkhof EM, Smeenk RJ, et al. Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized Phase III trial. J Clin Oncol. 2021;39(7):787–96.
https://doi.org/10.1200/JCO.20.02873 DOI: https://doi.org/10.1200/JCO.20.02873
Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399(10323):447–60. DOI: https://doi.org/10.1016/S0140-6736(21)02437-5
Kupelian PA, Buchsbaum JC, Elshaikh M, Reddy CA, Zippe C, Klein EA. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above. Cancer. 2002;95(11):2302–7.
https://doi.org/10.1002/cncr.10977 DOI: https://doi.org/10.1002/cncr.10977
Shore ND, Moul JW, Pienta KJ, Czernin J, King MT, Freedland SJ. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. Prostate Cancer Prostatic Dis. 2024;27(2):192–201.
https://doi.org/10.1038/s41391-023-00712-z DOI: https://doi.org/10.1038/s41391-023-00712-z
Yamazaki H, Yoshioka Y, Inoue T, Tanaka E, Nishikubo M, Sato T, et al. Changes in natural killer cell activity by external radiotherapy and/or brachytherapy. Oncol Rep. 2002 Mar;9(2):359–63.) DOI: https://doi.org/10.3892/or.9.2.359
McGinnes K, Florence J, Penny R. The effect of radiotherapy on the natural killer (NK)-cell activity of cancer patients. J Clin Immunol. 1987;7(3):210–7.
https://doi.org/10.1007/BF00915726 DOI: https://doi.org/10.1007/BF00915726
Baude J, Limagne E, Ladjohounlou R, Mirjolet C. Chapter two – combining radiotherapy and NK cell-based therapies: the time has come. In: Mirjolet C, Galluzzi L, editors. International review of cell and molecular biology. Academic Press; 2023, pp. 31–60. DOI: https://doi.org/10.1016/bs.ircmb.2023.02.003
Wen SWC, Nederby L, Andersen RF, Hansen TS, Nyhus CH, Hilberg O, et al. NK cell activity and methylated HOXA9 ctDNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors. Br J Cancer. 2023;129(1):135–42.
https://doi.org/10.1038/s41416-023-02285-z DOI: https://doi.org/10.1038/s41416-023-02285-z
Henriksen JR, Nederby L, Donskov F, Waldstrøm M, Adimi P, Jakobsen A, et al. Blood natural killer cells during treatment in recurrent ovarian cancer. Acta Oncol. 2020;59(11):1365–73.
https://doi.org/10.1080/0284186X.2020.1791358 DOI: https://doi.org/10.1080/0284186X.2020.1791358
Provençal M, Rioux L, Jobin G, Katia B, Rodriguez-Suarez R. A253 Measurement of natural killer cell activity (NKA) in subjects undergoing colonoscopy: test performance of a new blood test at different cut-offs for the detection of colorectal cancer (CRC). J Can Assoc Gastroenterol. 2018;1(suppl_1):440.
https://doi.org/10.1093/jcag/gwy008.254 DOI: https://doi.org/10.1093/jcag/gwy008.254
Brauning A, Rae M, Zhu G, Fulton E, Admasu TD, Stolzing A, et al. Aging of the immune system: focus on natural killer cells phenotype and functions. Cells. 2022;11(6):1017.
https://doi.org/10.3390/cells11061017 DOI: https://doi.org/10.3390/cells11061017
Jung YS, Park JH, Park DI, Sohn CI, Lee JM, Kim TI. Impact of smoking on human natural killer cell activity: a large cohort study. J Cancer Prev. 2020;25(1):13–20.
https://doi.org/10.15430/JCP.2020.25.1.13 DOI: https://doi.org/10.15430/JCP.2020.25.1.13
Canter RJ, Judge SJ, Collins CP, Yoon DJ, Murphy WJ. Suppressive effects of obesity on NK cells: is it time to incorporate obesity as a clinical variable for NK cell-based cancer immunotherapy regimens? J Immunother Cancer. 2024;12(3):e008443.
https://doi.org/10.1136/jitc-2023-008443 DOI: https://doi.org/10.1136/jitc-2023-008443
Jung YS, Park JH, Park DI, Sohn CI, Lee JM, Kim TI. Physical inactivity and unhealthy metabolic status are associated with decreased natural killer cell activity. Yonsei Med J. 2018;59(4):554–62.
https://doi.org/10.3349/ymj.2018.59.4.554 DOI: https://doi.org/10.3349/ymj.2018.59.4.554
Viel S, Besson L, Charrier E, Marçais A, Disse E, Bienvenu J, et al. Alteration of natural killer cell phenotype and function in obese individuals. Clin Immunol. 2017;177:12–7.
https://doi.org/10.1016/j.clim.2016.01.007 DOI: https://doi.org/10.1016/j.clim.2016.01.007
Kucuksezer UC, Aktas Cetin E, Esen F, Tahrali I, Akdeniz N, Gelmez MY, et al. The role of natural killer cells in autoimmune
diseases. Front Immunol. 2021;12:622306.
https://doi.org/10.3389/fimmu.2021.622306 DOI: https://doi.org/10.3389/fimmu.2021.622306
Qin R, Qin J, Li X, Xu Z, He P, Yuan X, et al. Influence of immunosuppressive drugs on natural killer cells in therapeutic drug exposure in liver transplantation. Hepatobiliary Surg Nutr. 2023;12(6):835–53.
https://doi.org/10.21037/hbsn-22-438 DOI: https://doi.org/10.21037/hbsn-22-438
Hansen TF, Nederby L, Zedan AH, Mejlholm I, Henriksen JR, Steffensen KD, et al. Correlation between natural killer cell activity and treatment effect in patients with disseminated cancer. Transl Oncol. 2019;12(7):968–72.
https://doi.org/10.1016/j.tranon.2019.04.002 DOI: https://doi.org/10.1016/j.tranon.2019.04.002
Pasero C, Gravis G, Granjeaud S, Guerin M, Thomassin-Piana J, Rocchi P, et al. Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer. Oncotarget. 2015;6(16):14360–73. DOI: https://doi.org/10.18632/oncotarget.3965
Zedan AH, Nederby L, Volmer LM, Madsen CV, Sørensen BE, Hansen TF. Natural killer cell activity in metastatic castration resistant prostate cancer patients treated with enzalutamide. Sci Rep. 2023;13:17144.
https://doi.org/10.1038/s41598-023-43937-7 DOI: https://doi.org/10.1038/s41598-023-43937-7
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Stine V. Eriksen, Christine V. Madsen, Signe Timm, Ahmed H. Zedan, Louise Raunkilde, Torben F. Hansen, Line Nederby
This work is licensed under a Creative Commons Attribution 4.0 International License.
